(0.22%) 5 143.00 points
(0.21%) 38 522 points
(0.32%) 17 903 points
(-0.99%) $83.02
(1.66%) $1.955
(-0.32%) $2 339.70
(-0.29%) $27.46
(0.28%) $924.70
(-0.16%) $0.933
(-0.08%) $11.02
(-0.24%) $0.798
(0.77%) $92.58
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.14%
@ $28.94
发出时间: 15 Feb 2024 @ 02:53
回报率: -24.05%
上一信号: Feb 14 - 04:50
上一信号:
回报率: 0.59 %
Live Chart Being Loaded With Signals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases...
Stats | |
---|---|
今日成交量 | 858 483 |
平均成交量 | 728 017 |
市值 | 1.99B |
EPS | $0 ( 2024-02-26 ) |
下一个收益日期 | ( $-0.690 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.53 |
ATR14 | $0.0190 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Militello John | Sell | 833 | Common Stock |
2024-04-12 | Southwell David P | Buy | 70 000 | Common Stock |
2024-04-15 | Southwell David P | Buy | 29 624 | Common Stock |
2024-04-15 | Southwell David P | Sell | 10 000 | Common Stock |
2024-04-12 | Southwell David P | Sell | 59 716 | Common Stock |
INSIDER POWER |
---|
41.55 |
Last 97 transactions |
Buy: 5 078 928 | Sell: 2 246 729 |
音量 相关性
Rocket Pharmaceuticals 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Rocket Pharmaceuticals 相关性 - 货币/商品
Rocket Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-7.10M (0.00 %) |
EPS: | $-2.92 |
FY | 2023 |
营收: | $0 |
毛利润: | $-7.10M (0.00 %) |
EPS: | $-2.92 |
FY | 2022 |
营收: | $0 |
毛利润: | $-6.27M (0.00 %) |
EPS: | $-3.22 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。